Medel R, Dieguez S, Brindo M, Ayuso S, Canepa C, Ruarte A, Podesta M L
Unidad de Urología, Laboratorio Central, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
Br J Urol. 1998 May;81 Suppl 3:46-9. doi: 10.1046/j.1464-410x.1998.00007.x.
To evaluate the 24-h diuresis, urinary osmolality, plasma arginine vasopressin (AVP) and urinary prostaglandin E2 (PGE2) before and during desmopressin treatment in patients with monosymptomatic primary enuresis (MPE), and to investigate the possible depressor effect of desmopressin on the detrusor in such patients with urodynamically confirmed bladder instability.
Seven healthy children (control group) and 11 consecutive patients with MPE (mean age 10.4 years, range 7-15) were assessed using laboratory tests, renal and bladder ultrasonography, and video-urodynamic investigations. A 24-h inpatient assessment with a controlled water intake of 20 mL/kg per day included determinations of diuresis, urinary osmolality, AVP and PGE2 in both normal children and those with MPE. After 30 days of treatment at optimal doses of desmopressin, all children were hospitalized and re-evaluated during desmopressin treatment; all completed 3 months of treatment at optimal doses. At the end of this period, patients whose symptoms improved by > or = 80% were defined as 'responders' while those in whom they did not were defined as 'non-responders'.
After treatment, six of the 11 patients with MPE were 'responders' and five 'non-responders'. Urodynamic evaluation showed bladder instability in seven of the 11 patients with MPE but in those with bladder dysfunction, urodynamic studies carried out during desmopressin treatment showed no changes in detrusor activity. There were significant differences in the morning values of AVP between normal children and responders (P < 0.03), and between responders and non-responders (P < 0.02); none of the non-responders had AVP levels of < 2.5 pg/mL, while none of the responders exceeded this value. At midnight, responders had the lowest mean AVP and non-responders the highest; this correlated with the highest PGE2 value in the nonresponders at 00.00-08.00 hours. Non-responders had an overnight mean PGE2 level greater than that in normal subjects or responders.
Polyuria occurred in all patients with MPE, independently of the response to desmopressin. Responders had the lowest AVP values over the 24 h; the morning AVP levels differentiated normal subjects from enuretic patients and responders from non-responders. In patients with MPE, clinically undetected bladder instability was unrelated to the results of treatment and there were no urodynamic changes during desmopressin treatment. The differences between enuretic patients suggested a different aetiology of MPE, probably related to an increase in PGE2 concentration and an antagonistic mechanism of action of AVP or desmopressin.
评估去氨加压素治疗单纯症状性原发性遗尿症(MPE)患者之前及治疗期间的24小时尿量、尿渗透压、血浆精氨酸加压素(AVP)和尿前列腺素E2(PGE2),并研究去氨加压素对经尿动力学证实存在膀胱不稳定的此类患者逼尿肌的可能降压作用。
对7名健康儿童(对照组)和11例连续的MPE患者(平均年龄10.4岁,范围7 - 15岁)进行实验室检查、肾脏和膀胱超声检查以及影像尿动力学检查。在每天20 mL/kg的控制饮水量下进行24小时住院评估,包括测定正常儿童和MPE患者的尿量、尿渗透压、AVP和PGE2。在以最佳剂量的去氨加压素治疗30天后,所有儿童住院并在去氨加压素治疗期间重新评估;所有患者均完成了3个月的最佳剂量治疗。在此期间结束时,症状改善≥80%的患者被定义为“反应者”,而未改善的患者被定义为“无反应者”。
治疗后,11例MPE患者中有6例为“反应者”,5例为“无反应者”。尿动力学评估显示,11例MPE患者中有7例存在膀胱不稳定,但在膀胱功能障碍患者中,去氨加压素治疗期间进行的尿动力学研究显示逼尿肌活动无变化。正常儿童与反应者之间(P < 0.03)以及反应者与无反应者之间(P < 0.02)的AVP早晨值存在显著差异;无反应者中无一例AVP水平<2.5 pg/mL,而反应者中无一例超过此值。午夜时,反应者的平均AVP最低,无反应者最高;这与无反应者在00:00 - 08:00时最高的PGE2值相关。无反应者的夜间平均PGE2水平高于正常受试者或反应者。
所有MPE患者均出现多尿,与对去氨加压素的反应无关。反应者在24小时内的AVP值最低;早晨的AVP水平区分了正常受试者与遗尿患者以及反应者与无反应者。在MPE患者中,临床未检测到的膀胱不稳定与治疗结果无关,且去氨加压素治疗期间尿动力学无变化。遗尿患者之间的差异提示MPE的病因不同,可能与PGE2浓度升高以及AVP或去氨加压素的拮抗作用机制有关。